2 July 2022

Dashraath P, Nielsen-Saines K, Mattar C, Musso D, Tambyah P, Baud D. Guidelines for pregnant individuals with monkeypox virus exposure. Lancet. 2022 Jul 2;400(10345):21-22. PubMed: https://pubmed.gov/35750071. Full text: https://doi.org/10.1016/S0140-6736(22)01063-7

Clinicians should maintain a high index of suspicion for monkeypox virus in any pregnant woman presenting with lymphadenopathy and vesiculopustular rash—including rash localised to the genital or perianal region—even if there are no apparent epidemiological links. The authors propose a clinical management algorithm for pregnant women with suspected monkeypox virus exposure (see the figure).

 

27 June 2022

Khalil A, Samara A, O’Brien P, et al. Monkeypox vaccines in pregnancy: lessons must be learned from COVID-19. Lancet Glob Health. 2022 Jun 27:S2214-109X(22)00284-4. PubMed: https://pubmed.gov/35772413. Full text: https://doi.org/10.1016/S2214-109X(22)00284-4

Currently, no vaccine against monkeypox is approved for use in pregnancy. Because MVA-BN (EU: Imvanex; US: JYNNEOS) is a non-replicating vaccine, there is no theoretical reason for concern about its use in pregnancy. However, “MVA-BN should be avoided during pregnancy unless the possible benefits in terms of preventing monkeypox outweigh any potential unknown risk of the vaccine.” MVA-BN is considered safe in breastfeeding.

 

3 June 2022

Khalil A, Samara A, O’Brien P, et al. Monkeypox and pregnancy: what do obstetricians need to know? Ultrasound Obstet Gynecol. 2022 Jul;60(1):22-27. PubMed: https://pubmed.gov/35652380. Full text: https://doi.org/10.1002/uog.24968

A summary for obstetricians.